A deficiency of uPAR alters endothelial angiogenic function and cell morphology

Vascular Cell

Volumn 3, Issue , 2011, Pages

  Balsara, Rashna D ^a   Merryman, Reid ^a   Virjee, Farhaad ^a   Northway, Claire ^a   Castellino, Francis J ^a   Ploplis, Victoria A ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BETA1 INTEGRIN; FOCAL ADHESION KINASE; MATRIGEL; PAXILLIN; RAC1 PROTEIN; UROKINASE RECEPTOR; VASCULOTROPIN; VITRONECTIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CAPILLARY TUBE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

MURINAE; MUS;

EID: 84858185716     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-3-10     Document Type: Article

References (76)

1. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Ingber DE, Circ Res 2002 15 877 887 (Pubitemid 35373587)
2. The role of the plasminogen activation system in angiogenesis and metastasis. Rabbani SA, Mazar AP, Surg Oncol Clin N Am 2001 10 393 415 11382594 (Pubitemid 32472537)
3. A reevaluation of integrins as regulators of angiogenesis. Hynes RO, Nat Med 2002 8 918 921 10.1038/nm0902-918 12205444 (Pubitemid 35033683)
4. Mechanisms of angiogenesis and arteriogenesis. Carmeliet P, Nat Med 2000 6 389 395 10.1038/74651 10742145 (Pubitemid 30208155)
5. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK, Proc Natl Acad Sci USA 1985 82 4939 4943 10.1073/pnas.82.15.4939 2991901 (Pubitemid 15249921)
6. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. Vassalli JD, Baccino D, Belin D, J Cell Biol 1985 100 86 92 10.1083/jcb.100.1.86 3880760 (Pubitemid 15151884)
7. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. Stephens RW, Pöllänen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, Rønne E, Behrendt N, Danø K, Vaheri A, J Cell Biol 1989 108 1987 1995 10.1083/jcb.108.5.1987 2523891 (Pubitemid 19130529)
8. Identification of the urokinase receptor as an adhesion receptor for vitronectin. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA, J Biol Chem 1994 1269 32380 32388
9. uPAR: a versatile signalling orchestrator. Carmeliet P, Nat Rev Mol Cell Biol 2002 3 932 943 10.1038/nrm977 12461559 (Pubitemid 35477371)
10. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. Kjøller L, Hall A, J Cell Biol 2001 152 1145 1157 10.1083/jcb.152.6.1145 11257116 (Pubitemid 34280173)
11. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. Hedman K, Nielsen LS, Danø K, Vaheri A, J Cell Biol 1988 106 87 95 10.1083/jcb.106.1.87 3123496 (Pubitemid 18051396)
12. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. Myöhänen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Høyer-Hansen G, Danø K, Vaheri A, J Histochem Cytochem 1993 41 1291 1301 10.1177/41.9.8394852 8394852 (Pubitemid 23239093)
13. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Pyke C, Graem N, Ralfkiaer E, Rønne E, Høyer-Hansen G, Brünner N, Danø K, Cancer Res 1993 53 1911 1915 8385573 (Pubitemid 23127124)
14. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Pyke C, Ralfkiaer E, Rønne E, Høyer-Hansen G, Kirkeby L, Danø K, Histopathology 1994 24 131 138 10.1111/j.1365-2559.1994.tb01291.x 8181805 (Pubitemid 24192274)
15. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. Rømer J, Pyke C, Lund LR, Ralfkiaer E, Danø K, J Invest Dermatol 2001 116 353 358 10.1046/j.1523-1747.2001.01241.x 11231307 (Pubitemid 32202898)
16. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Nielsen BS, Rank F, Illemann M, Lund LR, Danø K, Int J Cancer 2007 120 2086 2095 10.1002/ijc.22340 17290405 (Pubitemid 46555845)
17. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS, J Biol Chem 2005 280 36529 36540 10.1074/jbc.M503111200 16127174 (Pubitemid 41633927)
18. Down-regulation of uPAR and cathepsin B retards cofilin dephosphorylation. Gondi CS, Kandhukuri N, Kondraganti S, Gujrati M, Olivero WC, Dinh DH, Rao JS, Int J Oncol 2006 28 633 639 16465367
19. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling. Xue A, Xue M, Jackson C, Smith RC, Int J Biochem Cell Biol 2009 41 1731 1738 10.1016/j.biocel.2009.03.004 19433314
20. uPAR-induced cell adhesion and migration: vitronectin provides the key. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N, J Cell Biol 2007 177 927 939 10.1083/jcb.200612058 17548516 (Pubitemid 46873097)
21. Composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. Hillig T, Engelholm LH, Ingvarsen S, Madsen DH, Gårdsvoll H, Larsen JK, Ploug M, Danø K, Kjøller L, Behrendt NA, J Biol Chem 2008 283 15217 15223 10.1074/jbc.C700214200 18362146
22. Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Gondi CS, Rao JS, Methods Mol Biol 2009 487 267 281 19301652
23. Generation and characterization of urokinase receptor-deficient mice. Dewerchin M, Nuffelen AV, Wallays G, Bouche A, Moons L, Carmeliet P, Mulligan RC, Collen D, J Clin Invest 1996 97 870 878 10.1172/JCI118489 8609247 (Pubitemid 26057107)
24. Enhanced in vitro proliferation of aortic endothelial cells from plasminogen activator inhibitor-1-deficient mice. Ploplis VA, Balsara R, Sandoval-Cooper MJ, Yin ZJ, Batten J, Modi N, Gadoua D, Donahue D, Martin JA, Castellino FJ, J Biol Chem 2004 279 6143 6151 14625301 (Pubitemid 38220647)
25. Continuous endothelial cell activation increases angiogenesis: evidence for the direct role of endothelium linking angiogenesis and inflammation. Rajashekhar G, Willuweit A, Patterson CE, Sun P, Hilbig A, Breier G, Helisch A, Clauss M, J Vasc Res 2006 43 193 204 10.1159/000090949 16410682 (Pubitemid 43248001)
26. Role of cell shape in growth control. Folkman J, Moscona A, Nature (Lond.) 1978 273 345 349 10.1038/273345a0 (Pubitemid 8344174)
27. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. Waltz DA, Chapman HA, J Biol Chem 1994 269 14746 14750 7514182 (Pubitemid 24194041)
28. Regulation of integrin function by the urokinase receptor. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA, Science 1996 273 1551 1555 10.1126/science.273.5281.1551 8703217 (Pubitemid 26301666)
29. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. Yebra M, Parry GC, Strömblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA, J Biol Chem 1996 271 29393 29399 10.1074/jbc.271.46.29393 8910604 (Pubitemid 26382657)
30. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F, Proc Natl Acad Sci USA 2002 99 1359 1364 10.1073/pnas.022652999 11818541 (Pubitemid 34136498)
31. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. Cubellis MV, Wun TC, Blasi F, EMBO J 1990 9 1079 85 2157592
32. Low concentrations of nocodazole interfere with fibroblast locomotion without significantly affecting microtubule level: implications for the role of dynamic microtubules in cell locomotion. Liao G, Nagasaki T, Gundersen GG, J Cell Sci 1995 108 3473 3483 8586659
33. Regulation of microtubules in cell migration. Watanabe T, Noritake J, Kaibuchi K, Trends Cell Biol 2005 15 76 83 10.1016/j.tcb.2004.12.006 15695094 (Pubitemid 40188217)
34. Positive feedback interactions between microtubule and actin dynamics during cell motility. Waterman-Storer CM, Salmon E, Curr Opin Cell Biol 1999 11 61 67 10.1016/S0955-0674(99)80008-8 10047528 (Pubitemid 29084133)
35. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Burridge K, Fath K, Kelly T, Nuckolls G, Turner C, Annu Rev Cell Biol 1988 4 487 525 10.1146/annurev.cb.04.110188.002415 3058164 (Pubitemid 19139264)
36. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. Burridge K, Turner CE, Romer LH, J Cell Biol 1992 119 893 903 10.1083/jcb.119.4.893 1385444
37. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Calalb MB, Polte TR, Hanks SK, Mol Cell Biol 1995 15 954 63 7529876
38. Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. Calalb MB, Zhang X, Polte TR, Hanks SK, Biochem Biophys Res Commun 1996 228 662 8 10.1006/bbrc.1996.1714 8941336 (Pubitemid 26421437)
39. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Schlaepfer DD, Hanks SK, Hunter T, van der Geer P, Nature 1994 372 786 791 7997267
40. Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases. Schlaepfer DD, Hunter T, Mol Cell Biol 16 5623 33 Erratum in: Mol. Cell. Biol. 1996, 16:7182-184
41. SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Westhoff MA, Serrels B, Fincham VJ, Frame MC, Carragher NO, Mol Cell Biol 2004 24 8113 8133 10.1128/MCB.24.18.8113- 8133.2004 15340073 (Pubitemid 39167461)
42. Targeting membrane-localized focal adhesion kinase to focal adhesions: roles of tyrosine phosphorylation and SRC family kinases. Katz BZ, Romer L, Miyamoto S, Volberg T, Matsumoto K, Cukierman E, Geiger B, Yamada KM, J Biol Chem 2003 278 29115 29120 10.1074/jbc.M212396200 12754219 (Pubitemid 36935826)
43. Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase. Bellis SL, Miller JT, Turner CE, J Biol Chem 1995 270 17437 17441 10.1074/jbc.270.29.17437 7615549
44. Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: a role for paxillin tyrosine phosphorylation. Richardson A, Malik RK, Hildebrand JD, Parsons JT, Mol Cell Biol 1997 17 6906 6914 9372922 (Pubitemid 27505920)
45. Roles of microfilaments and microtubules in paxillin dynamics. Hu YL, Haga JH, Miao H, Wang Y, Li YS, Chien S, Biochem Biophys Res Commun 2006 348 1463 1471 10.1016/j.bbrc.2006.08.022 16920067 (Pubitemid 44291362)
46. Actopaxin, a new focal adhesion protein that binds paxillin LD motifs and actin and regulates cell adhesion. Nikolopoulos SN, Turner CE, J Cell Biol 2000 151 1435 1448 10.1083/jcb.151.7.1435 11134073 (Pubitemid 32047593)
47. Regulation of vinculin binding to talin and actin by phosphatidyl- inositol-4-5-bisphosphate. Gilmore AP, Burridge K, Nature 1996 381 531 535 10.1038/381531a0 8632828 (Pubitemid 26170933)
48. Rho GTPases and signaling networks. Van Aelst L, D'Souza-Schorey C, Genes Dev 1997 11 2295 322 10.1101/gad.11.18.2295 9308960 (Pubitemid 27408529)
49. Multifaceted role of Rho proteins in angiogenesis. Merajver SD, Usmani SZ, J Mammary Gland Biol Neoplasia 2005 10 291 298 10.1007/s10911-006-9002-8 16900393 (Pubitemid 44256409)
50. Interplay between Rac and Rho in the control of substrate contact dynamics. Rottner K, Hall A, Small JV, Current Biol 1999 9 640 648 10.1016/S0960-9822(99)80286-3 (Pubitemid 29291944)
51. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Burridge K, Fath K, Kelly T, Nuckolls G, Turner C, Annu Rev Cell Biol 1988 4 487 525 10.1146/annurev.cb.04.110188.002415 3058164 (Pubitemid 19139264)
52. Integrins: versatility, modulation, and signaling in cell adhesion. Hynes RO, Cell 1992 69 11 25 10.1016/0092-8674(92)90115-S 1555235
53. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Xue W, Mizukami I, Todd RF, Petty HR, Cancer Res 1997 57 1682 1689 9135008 (Pubitemid 27199659)
54. STAT1 activation during monocyte to macrophage maturation: role of adhesion molecules. Coccia EM, Del Russo N, Stellacci E, Testa U, Marziali G, Battistini A, Int Immunol 1999 11 1075 1083 10.1093/intimm/11.7.1075 10383940 (Pubitemid 29338749)
55. Hyaluronan-Mediated leukocyte adhesion and dextran sulfate sodium-induced colitis Are attenuated in the absence of Signal transducer and activator of transcription 1. Bandyopadhyay SK, de la Motte CA, Kessler SP, Hascall VC, Hill DR, Strong SA, Am J Path 2008 173 1361 1368 10.2353/ajpath.2008.080444 18818378
56. Fibrin II induces endothelial cell capillary tube formation. Chalupowicz DG, Chowdhury ZA, Bach TL, Barsigian C, Martinez J, J Cell Biol 1995 130 207 215 10.1083/jcb.130.1.207 7540617
57. Fibrinogen induces adhesion, spreading, and microfilament organization of human endothelial cells in vitro. Dejana E, Colella S, Languino LR, Balconi G, Corbascio GC, Marchisio PC, J Cell Biol 1987 104 1403 1411 10.1083/jcb.104.5. 1403 2437130 (Pubitemid 17084498)
58. Participation of the urokinase receptor in neutrophil efferocytosis. Park YJ, Liu G, Tsuruta Y, Lorne E, Abraham E, Blood 2009 114 860 870 10.1182/blood-2008-12-193524 19398720
59. How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Mohri H, Ohkubo T, Am J Clin Pathol 1991 96 605 609 1719797
60. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT, Nature Medicine 1996 2 529 533 10.1038/nm0596-529 8616710 (Pubitemid 26151516)
61. Vitronectin expression in rheumatoid arthritic synovia - inhibition of plasmin generation by vitronectin produced in vitro. Tomasini-Johansson BR, Milbrink J, Pejler G, Br J Rheumatol 1998 37 620 629 10.1093/rheumatology/37.6. 620 9667615
62. Structure and function of vitronectin. McKeown-Longo PJ, Panetti TS, Trends Glycosci Glycotechnol 1996 8 327 340
63. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. Aguirre Ghiso JA, Kovalski K, Ossowski L, J Cell Biol 1999 147 89 104 10.1083/jcb.147.1.89 10508858 (Pubitemid 30211799)
64. A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. Chaurasia P, Aguirre-Ghiso JA, Liang OD, Gardsvoll H, Ploug M, Ossowski L, J Biol Chem 2006 281 14852 14863 10.1074/jbc.M512311200 16547007 (Pubitemid 43855190)
65. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Dass CR, Anne P, Nadesapillai W, Robin D, Howard ML, Fisher JL, Zhou H, Choong PF, Clinical and Experimental Metastasis 2005 22 643 652 10.1007/s10585-006-9004-3 16649073 (Pubitemid 44259525)
66. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA, J Cell Biol 1999 144 1285 1294 10.1083/jcb.144.6.1285 10087270 (Pubitemid 29157305)
67. Signalling via integrins: Implications for cell survival and anticancer strategies. Hehlgans S, Haase M, Cordes N, Biochimica et Biophysica Acta 2007 1775 163 180 17084981 (Pubitemid 44881199)
68. FAK engages multiple pathways to maintain survival of fibroblasts and epithelia-differential roles for paxillin and p130Cas. Zouq NK, Keeble JA, Lindsay J, Valentijn AJ, Zhang L, Mills D, Turner CE, Streuli CH, Gilmore AP, J Cell Sci 2009 122 357 367 10.1242/jcs.030478 19126677
69. Focal adhesion kinase activates Stat1 in integrin-mediated cell migration and adhesion. Xie B, Zhao J, Kitagawa M, Durbin J, Madri JA, Guan JL, Fu XY, J Biol Chem 2001 276 19512 19523 10.1074/jbc.M009063200 11278462
70. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS, Oncogene 2004 23:8486 8496 10.1038/sj.onc. 1207879 15378018 (Pubitemid 39540799)
71. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Margheri F, Manetti M, Serrat S, Nosi D, Pucci M, Matucci-Cerinic M, Kahaleh B, Bazzichi L, Fibbi G, Ibba-Manneschi L, Del Rosso M, Arthritis Rheum 2006 54 3926 3938 10.1002/art.22263 17133606 (Pubitemid 44955896)
72. Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. Furlan F, Galbiati C, Jorgensen NR, Jensen JE, Mrak E, Rubinacci A, Talotta F, Verde P, Blasi F, J Bone Miner Res 2007 22 1387 96 10.1359/jbmr.070516 17539736 (Pubitemid 351339683)
73. Modification of kidney barrier function by the urokinase receptor. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J, Nat Med 2008 14 55 63 10.1038/nm1696 18084301
74. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T, J Immunol 2002 168 3507 3511 11907112 (Pubitemid 34250418)
75. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT, J Exp Med 1998 188 1029 37 10.1084/jem.188.6.1029 9743521 (Pubitemid 28443326)
76. Genetic Disruption of Cortical Interneuron Development Causes Region- and GABA Cell Type Specific Deficits, Epilepsy, and Behavioral Dysfunction. Powell EM, Campbell DB, Stanwood GD, Davis C, Noebels JL, Levitt P, The J Neuroscience 2003 23 622 631 (Pubitemid 36139561)